At what enterprise value was DESSINTEY acquired in 2025?

You can find the full valuation details of DESSINTEY on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DESSINTEY when it was acquired by ARLANE?

The exact EV/EBITDA multiple for DESSINTEY is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was DESSINTEY acquired by ARLANE?

DESSINTEY was acquired by ARLANE in 2025.

What was the revenue of DESSINTEY at the time of the deal?

The revenue of DESSINTEY at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DESSINTEY acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DESSINTEY deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.turennecapital.com/turenne-sante-orchestre-la-sortie-de-relyens-innovation-sante-avec-la-prise-de-participation-majoritaire-de-dessintey-par-arlane/

← DATABASE

Home Database Healthcare & PharmaDESSINTEY

11/2025

DESSINTEY acquired by ARLANE

FRANCE Life Sciences / Medical Devices REV 5M - 25M EUR

Context

Arlane has acquired a majority stake (approximately two-thirds) in Dessintey through a primary LBO. The transaction allows for the exit of early-stage investors Turenne Sante (via Relyens Innovation Sante) and Credit Agricole Haute-Loire, who invested in 2019. The three founders (Nicolas Fournier, Davy Luneau, Pascal Giraux) and key managers have reinvested alongside Arlane but are diluting their stakes. The deal is supported by a conservative senior debt package provided by CIC and LCL.

DESSINTEY, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Dessintey is a French MedTech company specializing in intensive motor rehabilitation. It develops and markets intelligent devices aimed at patients recovering from strokes, trauma, or neurological disorders. Its technology typically uses visual illusion/simulation to stimulate brain plasticity. The company is profitable and present in France, Germany, Switzerland, and Austria.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
01/2026	YOTTA CAPITAL	VILLARD	FRANCE	Life Sciences	Yotta Capital Partners led a majority buyout of Villard, succeeding the previous sponsorless structure held by CEO. The transaction values the company on a solid growth trajectory, with the management team and historical regional partners reinvesting in the new pool
12/2025	CHARTERHOUSE	WINBACK	FRANCE	Life Sciences	Charterhouse Capital Partners acquired a majority equity stake in Winback following a competitive process that attracted interest from several top-tier private equity funds. This transaction facilitates the exit of Capza, which had supported the company since late 2021 through a minority "flex equity" structure, and allows the founding duo to cash out a portion of their holdings while reinvesting to remain significant minority shareholders and operational leaders
11/2025	ANJAC BEAUTY & HEALTH	HEALTH CHAIN GROUP (HCG)	SLOVENIA	Life Sciences	Anjac acquired a majority stake in HCG to accelerate its growth in the nutraceutical space. This is the 17th company to join the Anjac ecosystem. Beyond the acquisition cost, Anjac has committed to a EUR25M investment plan to expand the Velenje production site, aiming to triple its output within 12 months
11/2025	PFIZER	METSERA	UNITED STATES	Life Sciences	Pfizer has finalized the acquisition of Metsera, an operation designed to fundamentally transform the group’s Internal Medicine portfolio and secure a leading foothold in the obesity treatment sector. The strategic rationale for this transaction centers on a "pipeline-transformation" play, merging the target's highly differentiated clinical-stage obesity candidates with the group's global development and commercial infrastructure
10/2025	PUBLIC MARKETS (IPO)	OTTOBOCK	GERMANY	Life Sciences	Ottobock successfully completed its Initial Public Offering on the Frankfurt Stock Exchange, marking the largest German IPO of 2025. The shares were priced at €66.00, with the first trading price reaching €72
09/2025	INVESTCorporate	DCC HEALTHCARE	UNITED KINGDOM	Life Sciences	InvestIndustrial finalized the acquisition of DCC Healthcare Limited from the London-listed group DCC plc. This transaction is a strategic corporate carve-out designed to simplify DCC plc's operations, allowing the group to focus resources on its largest and most profitable Energy division
09/2025	CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENT	PROTEOR	FRANCE	Life Sciences	Proteor has orchestrated a secondary Owner Buy-Out (OBO Bis). The transaction allows Ardian Growth to exit its minority position, which it held since the primary OBO in 2021, realizing a return of approximately 3x money
09/2025	CAPVEST PARTNERS	STADA	GERMANY	Life Sciences	CapVest Partners agreed to acquire a controlling majority stake in Stada from Bain Capital and Cinven. This deal serves as an alternative to a planned IPO in Frankfurt, which was shelved due to market volatility
08/2025	TERUMO	ORGANOX	UNITED KINGDOM	Life Sciences	Lauxera Capital Partners has successfully finalized the divestment of its minority equity stake in UK-based OrganOx to Japanese medical giant Terumo, marking the first historical exit for the medtech-focused growth investor
08/2025	WARBURG PINCUS	SEBIA	FRANCE	Life Sciences	The French medical diagnostics giant Sebia welcomes a new heavyweight investor, Warburg Pincus, into its capital. This transaction, valuing the company at over EUR5 billion, sees the partial exit of minority shareholders CDPQ and ICG

REFERENCES

Revenue range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DESSINTEY by ARLANE are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: arlane